Nectin-4

Nectin-4 Molekülinformation

Englischer Name	Nectin-4	Anzahl der inverkehr gebrachten Arzneimittel	1
Anzahl der klinischen Arzneimittel	29	Target-Alias	PRR4，LNIR，Nectin cell adhesion molecule 4，PVRL4，Ig superfamily receptor LNIR，Poliovirus receptor-related protein 4，NECTIN4，Poliovirus Receptor-Related 4，Nectin-4，Nectin 4，EDSS1
Höchste Forschungs- und Entwicklungsphase	Approved

Englischer Name	Nectin-4
Target-Alias	PRR4，LNIR，Nectin cell adhesion molecule 4，PVRL4，Ig superfamily receptor LNIR，Poliovirus receptor-related protein 4，NECTIN4，Poliovirus Receptor-Related 4，Nectin-4，Nectin 4，EDSS1
Anzahl der inverkehr gebrachten Arzneimittel	1
Anzahl der klinischen Arzneimittel	29
Höchste Forschungs- und Entwicklungsphase	Approved

Nectin-4 Produktliste

Attribut
Protein (23)Beads (1)Cell (1)Antibody (1)
Produktbibliothek
Online (26)
Spezies
Human (14)Mouse (6)Cynomolgus (4)Rat (2)
Etikett
His Tag (8)His Tag & Avi Tag (8)Fc Tag (4)- (3)Fc Tag & Avi Tag (3)
Marker
Unconjugated (12)Biotin-labeled (10)FITC Labeled (1)- (2)PE Labeled (1)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Vorbestellen/Bestellen
HOT NE4-H52H3	Human	HEK293	Human Nectin-4 Protein, His Tag (MALS verified)	In den Warenkorb legen
HOT NE4-H82E7	Human	HEK293	Biotinylated Human Nectin-4 Protein, His,Avitag™ (MALS verified)	In den Warenkorb legen
HOT NE4-M52H3	Mouse	HEK293	Mouse Nectin-4 Protein, His Tag (MALS verified)	In den Warenkorb legen
HOT NE4-M82E7	Mouse	HEK293	Biotinylated Mouse Nectin-4 Protein, His,Avitag™ (MALS verified)	In den Warenkorb legen
CHEK-ATP035	Human	HEK293	HEK293/Human Nectin-4 Stable Cell Line	In den Warenkorb legen
MBS-K039	Human	-	Human Nectin-4-coupled Magnetic Beads	In den Warenkorb legen
NE4-H5243	Human	HEK293	Human Nectin-4 (32-153) Protein, His Tag (MALS verified)	In den Warenkorb legen
NE4-H5255	Human	HEK293	Human Nectin-4 Protein, Fc Tag (MALS verified)	In den Warenkorb legen
NE4-H52E3	Human	HEK293	Unconjugated Human Nectin-4 Protein, His,Avitag™ (MALS verified)	In den Warenkorb legen
NE4-H82E3	Human	HEK293	Biotinylated Human Nectin-4 Protein, His,Avitag™ (MALS verified)	In den Warenkorb legen

Gesamtmenge26

Nectin-4 Molekülhintergrund

Nectin-4 (gene name PVRL4, poliovirus receptor-like 4) is a 66 kDa type I transmembrane glycoprotein belonging to the Nectin family of Ig superfamily proteins. Nectins are cell adhesion molecules that play a key role in various biological processes such as polarity, proliferation, differentiation and migration, for epithelial, endothelial, immune and neuronal cells, during development and adult life. Nectin-4 is a tumor-associated antigen in 50%, 49% and 86%o of breast, ovarian and lung carcinomas, respectively, mostly on tumors of bad prognosis. Its expression is not detected in the corresponding normal tissues.

Nectin-4 Molekülalias

NECTIN4,LNIR, PRR4, PVRL4

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
SYS-6002	SYS-6002; SYS6002; CRB-701	Phase 3 Clinical	CSPC Pharmaceutical Group Ltd, Jushi Biopharmaceutical Co Ltd	Carcinoma, Transitional Cell; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Uterine Cervical Neoplasms	Details
SHR-A2102	SHR-A2102	Phase 3 Clinical	Shanghai Hengrui Pharmaceutical Co Ltd	Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Metastatic breast cancer; Neoplasms; Pancreatic Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms	Details
Bulumtatug fuvedotin	9MW2821; 9MW-2821; 9-MW2821; 9-MW-2821	Phase 3 Clinical	Mabwell (Shanghai) Bioscience Co Ltd	Carcinoma; Carcinoma, Transitional Cell; Genital Neoplasms, Female; Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms; Uterine Cervical Neoplasms	Details
Zelenectide pevedotin	BT-8009	Phase 3 Clinical	Bicycle Tx Ltd	Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Ovarian Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms	Details
BT-7480	BT-7480	Phase 2 Clinical	Bicycle Therapeutics	Neoplasms; Solid tumours	Details
VBC-103	AVZO-103; VAC-103; VBC-103; VBC103	Phase 2 Clinical	VelaVigo Cayman Ltd	Carcinoma; Carcinoma, Transitional Cell; Solid tumours; Triple Negative Breast Neoplasms	Details
SC-101	SC-101	Phase 2 Clinical	Tianjin Conjustar Biotechnology Co Ltd	Breast Neoplasms; Solid tumours; Triple Negative Breast Neoplasms	Details
SKB-410	SKB410; SKB-410; MK-3120	Phase 2 Clinical	Sichuan Kelun-Biotech Biopharmaceutical Co Ltd	Neoplasms; Solid tumours; Urinary Bladder Neoplasms	Details
PSMA/NKG2DL/FAP-targeted Hi-TCR-T cells		Phase 1 Clinical	Shenzhen Misheng Biotechnology Co Ltd	Prostatic Neoplasms; Solid tumours	Details
BA-3361	BA3361; BA-3361	Phase 1 Clinical	Bioatla	Neoplasms	Details
ETx-22	ETx-22; LY4101174	Phase 1 Clinical	Emergence Therapeutics AG	Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Esophageal Neoplasms; Lung Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Pelvic Neoplasms; Prostatic Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms	Details
EB-DT-NK-UC101	EB-DT-NK-UC101	Phase 1 Clinical	Beijing Biotech	Carcinoma; Carcinoma, Transitional Cell; Urethral Neoplasms; Urinary Bladder Neoplasms	Details
68Ga-Nectin-4		Phase 1 Clinical	The First Affiliated Hospital Of Soochow University	Solid tumours	Details
[64Cu]Cu-AKY-1189	[64Cu]Cu-AKY-1189	Phase 1 Clinical	Aktis Oncology Inc	Neoplasms	Details
AKY-1189	AKY-1189; [225Ac]Ac-AKY-1189; 225Ac-AKY-1189	Phase 1 Clinical	Aktis Oncology Inc	Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms	Details
AK-146-D-1	AK146D1; AK-146-D1	Phase 1 Clinical		Solid tumours	Details
Nectin-4 targeting antibody drug conjugate 2 (Eli Lilly and Company)		Phase 1 Clinical	Eli Lilly And Company	Neoplasms	Details
Nectin-4 targeting antibody drug conjugate 1 (Eli Lilly and Company)		Phase 1 Clinical	Eli Lilly And Company	Neoplasms	Details
XKDCT-293	XKDCT-293; XKDCT293	Phase 1 Clinical	Shenzhen Celconta Life Science Co Ltd	Breast Neoplasms	Details
IPH-4502	IPH4502; IPH-4502	Phase 1 Clinical	Innate Pharma SA	Solid tumours	Details
LY-4052031	LY-4052031	Phase 1 Clinical	Eli Lilly & Company Lilly France	Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Esophageal Neoplasms; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Pelvic Neoplasms; Prostatic Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms	Details
RNDO-564	RNDO-564	Phase 1 Clinical	Rondo Therapeutics	Carcinoma; Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms	Details
ADRX-0706	ADRX-0706	Phase 1 Clinical	Adcentrx Therapeutics Inc	Carcinoma; Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms	Details
BAT-8007	BAT-8007	Phase 1 Clinical	Bio-Thera Solutions Ltd	Solid tumours	Details
Nectin-4 targeting radiopharmaceutical program (Aktis Oncology)		Clinical	Aktis Oncology Inc	Solid tumours	Details
[68Ga]Ga-NOTA-RND20		Clinical	Renji Hospital Affiliated To Shanghai Jiaotong University School Of Medicine	Digestive System Neoplasms	Details
[18F]F-RESCA-RND20		Clinical	Renji Hospital Affiliated To Shanghai Jiaotong University School Of Medicine	Digestive System Neoplasms	Details
CT-341	CT-341	Clinical	Shenzhen Celconta Life Science Co Ltd	Breast Neoplasms	Details
68Ga-N188	68Ga-N188; 68-Ga-N-188	Clinical	Yunnan Baiyao Group Co Ltd	Carcinoma, Transitional Cell; Neoplasms	Details

Inverkehr gebrachte Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Frühestes Markenname	Frühestes Genehmigungsland	Früheste Indikation	Früheste Genehmigungsgesellschaft	Früheste Genehmigungsdatum	Indikationen	Klinische Studie
Enfortumab vedotin	AGS-22C3E; AGS-22C3; ASG-22CE; AGS-M6; ASG-22M6E; DLE8519RWM; ASG-22ME; AGS-22ME; AGS-22M6E	Approved	Agensys Inc, Seagen Inc	Padcev, 备思复	United States	Carcinoma, Transitional Cell	Astellas Pharma Us Inc	2019-12-18	Carcinoma; Carcinoma in Situ; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Carcinoma, Transitional Cell; Colorectal Neoplasms; Endometrial Neoplasms; Intestinal Neoplasms; Kidney Neoplasms; Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Solid tumours; Ureteral Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms	Details

Produktrezensionen

O***s2022-07-30
0Menschen mögen
Biotinylated Human Nectin-4 (32-153) Protein, His,Avitag™ (MALS verified)
We used this for an important reagent in discovery campaigns. This was a great product! It came sooner than expected, which was awesome because we were able to easily make deadlines! It was also high quality. We didn't have any problems with it, so I am very happy with the quality of service and product. I will definitely buy again. Thank you very much.
1***82019-10-11
8Menschen mögen
Human Nectin-4 Protein, His Tag (MALS verified)
I Purchased this antigen for monoclonal antibody generation and antibody screening. The purity has been test by SDS-PAGE. It has a single band and no heterologous protein. It was used for antibody screening, and the screened antibody has a good affinity with the antigen.